Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (858)	11/19/2003 3:37:36 PM
From: Jibacoa	Read Replies (1) \| Respond to of 1005

Advexin is being administered in the form of an oral rinse, or mouthwash, for oral premalignancies... They had previously announced that on June 24.<g> corporate-ir.net I am long on INGN and keep thinking that both ADVEXIN and even more ING-241 have good prospects for FDA approval for cancer therapy. The stock needs to close above its November 14 H of 8.85 before it can test the October 21 H at 9.35 (After that the chart will look a lot better.<g>) Albeit the October 8 H of 10.20 and the September 18 H of 11.24 still represent a good deal of overhead resistance.<g> siliconinvestor.com I am still hopeful for the 15 level by the time of next year's ASCO meeting.<g> siliconinvestor.com RAGL Bernard